Publications by authors named "T Kogawa"
Background: Data on the desire for pregnancy and the status of fertility preservation (FP) in patients with breast cancer remain unclear. This study aimed to determine the status of patients with breast cancer who desired pregnancy and FP implementation before systemic therapy.
Methods: This retrospective study surveyed the institutional clinical databases and electronic medical records of patients aged < 43 years with stages 0-III primary breast cancer during surgery and treated between April 2020 and March 2021.
Article Synopsis
- Sacituzumab govitecan (SG) is an antibody-drug conjugate approved for treating metastatic triple-negative breast cancer (mTNBC) in various regions, with its safety and effectiveness evaluated in a Japanese study (ASCENT-J02).
- The study consisted of a phase 1 trial that determined the recommended dose (10 mg/kg), followed by a phase 2 trial focusing on the drug's efficacy and safety in patients with previously treated mTNBC.
- Results showed a 25.0% objective response rate at a median follow-up of 6.1 months, with manageable safety outcomes and no significant new safety concerns, confirming SG's efficacy and safety profile similar to earlier studies.
Background: Adolescents and young adults (AYAs) represent a small proportion of patients with cancer. The genomic profiles of AYA patients with cancer are not well-studied, and outcomes of genome-matched therapies remain largely unknown.
Patients And Methods: We investigated differences between Japanese AYA and older adult (OA) patients in genomic alterations, therapeutic evidence levels, and genome-matched therapy usage by cancer type.
Article Synopsis
- The JCOG0306 trial studied the effectiveness of neoadjuvant chemotherapy followed by radiation therapy in primary breast cancer, comparing the representative specimen (RS) method to the traditional total specimen (TS) method for evaluating pathological complete response (pCR).
- The study involved 103 patients, assessing pCR and quasi-pCR rates with both methods, and found that RS had a higher concordance rate with better identification of strong prognostic groups.
- Results indicated that both RS and TS methods provided similar prognostic outcomes for pCR groups, but RS method had significant advantages in differentiating patient survival rates more effectively than TS.
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer were updated and published online in 2023, and adapted, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with early breast cancer. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with breast cancer representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), co-ordinated by ESMO and KSMO. The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different Asian regions represented by the 10 oncological societies.
View Article and Find Full Text PDF